Mutations in JAK-STAT pathway genes and B-cell receptor (BCR)/NF-κB signaling genes have also been identified, but with lower frequencies. 11 Whole genome and exome sequencing studies to date have primarily focused on identification of small site mutations that are recurrent in FL tumorigenesis 8, 9 or involved in tumor clonal evolution. 11, 13 A comprehensive genomic and transcriptomic survey of multiple mutation types of different sizes in FL patients with detailed clinical annotations and long-term follow-up has not been accomplished. To gain insight into genetic biomarkers that may predict clinical features, we performed exome and whole genome mate-pair sequencing of fresh frozen tumor and paired peripheral blood DNAs, and transcriptome sequencing of tumor RNAs, from eight FL patients. This comprehensive genomic and transcriptomic profiling enables the detection of not only small site mutations (single nucleotide variants or SNVs; and small insertions and deletions or INDELs), but also large structural mutations such as copy number variants (CNVs), translocations and inversions in FL tumors. The patients sequenced were either below the median age of FL onset (n = 7, median 54.5 years old) or had a family history of FL (n = 1) ( Table 1 ). All samples were from the patient's initial diagnosis. These patients were clinically diverse, and included patients who had Grade 1 or 2 disease (n = 4), classified as 'indolent'; and patients with Grade 3a disease (n = 2) or who subsequently had pathologic transformation (n = 2), classified as 'aggressive' ( Table 1 ). An overview of all SNVs, small INDELs, large SVs and CNVs in individual patients is illustrated in Figures 1a-c , which highlights the genetic heterogeneity of these eight newly diagnosed FL. Our analysis of SNVs and INDELs revealed mutations in previously reported genes including MLL2, CREBBP, TNFRSF14 and histone cluster genes (HIST1H2AM and HIST1H2BD) ( Figure 1c and Supplementary File S1), although the mutation frequencies of some genes are lower in our samples. For example, MLL2 and CREBBP were reported to be mutated in 480% and 460% of the FL cases 9,11,12 whereas we detected MLL2 mutations in three out of eight cases (38%) and CREBBP mutations in two out of eight (25%) cases. In addition to the previously reported genes, we also identified novel recurrent mutations in cysteine-rich PAK1 inhibitor (CRIPAK) in two out of eight tumors. In a secondary analysis performed by Sanger sequencing in a second cohort of FL and diffuse large B-cell lymphoma (DLBCL) tumors, we identified CRIPAK mutations in 55% of FL (11 out of 20) and 38.7% of DLBCL (12 out of 31) tumors (Supplementary File S6, Figure A) . Bioinformatics analysis shows that the coding region of CRIPAK is highly enriched with the protein functional domain, post-SET, which is found in histone lysine methyltransferases genes including MLL2 and EZH2 that are known to be important in lymphomagenesis. Interestingly, CRIPAK is part of the same regulatory network of 31 genes including previously identified lymphoma genes such as MLL2, EZH2, CREBBP, EP300, TP53, MYC, STAT6 and BCL2, according to the shortest path algorithm by MetaCore (Philadelphia, Pennsylvania) (Supplementary File S4, Supplementary File S6 Figure A) . We showed that the connectivity between the 31 genes in this network is highly significant with an empirical P-value of 0 based on 10 000 simulations of calculating average pair-wise shortest distances from randomly chosen proteins from the protein-protein-interaction database (Supplementary File S6 Figure A) . Recurrent structural variants identified in the FL tumors included the well-known IGH-BCL2 translocation or t(14;18), in six out of eight cases (75%) and chromosome 1q amplifications in four out of eight (50%) tumors (Figure 1a , Supplementary Files S3 and S7). Other nonrecurrent large CNVs involving entire chromosomes or at arm levels, as well as other inter-and intrachromosomal structural variants were also detected in individual tumors (Figure 1a, Supplementary Files S3 and S7 ). In addition, we identified six fusion transcripts from the transcriptome sequencing data in three out of eight cases (38%) (Supplementary File S5, Supplementary File S6 Figure B) . Copy number alteration gains in 1q21-q31 have been reported in~50% of FL 14 and~20% of DLBCL 15 using nonsequencing based technologies including array comparative genomic hybridization and fluorescence in situ hybridization. The functional significance of the CNV gains in this region is still unknown. However, the prominent amplification of the region may indicate a potential role for this variant in lymphomagenesis.
Although our sample size was small, we found that SNVs and INDELs in MLL2, CREBBP, TNFRSF14, CRIPAK and histone cluster genes, as well as t(14;18), did not distinguish the indolent tumors from the aggressive tumors. However, gains in chr1q (4/4, 100%) and the presence of RNA fusion transcripts (3/4, 75%) were specific to aggressive tumors and were not detected in any of the indolent tumors. In addition, we found that the grade 3A tumors and the subsequently transformed tumors had higher numbers of genes with point mutations (SNVs and short INDELs) (40 ± 7.6 vs 26 ± 2.6; aggressive vs indolent), higher numbers of genes impacted by copy number alterations (1060 ± 263.7 vs 233 ± 133.9; aggressive vs indolent) and higher numbers of large SVs (24 ± 10 vs 6 ± 1.6; aggressive vs indolent) (Figure 1b) . Taken together, our comprehensive analysis of eight FL tumors reveals genetic diversity among newly diagnosed FL patients, identifies novel and recurrent mutations in CRIPAK, and finds that high tumor complexity and DNA instability may be indicators of more aggressive disease. 
